Tumor angiogenesis: causes, consequences, challenges and opportunities
By R. Lugano, Mohanraj Ramachandran, A. Dimberg. Cellular and Molecular Life Sciences, 2019
1,656 citations recorded by the source corpus.
Tumor vascularization occurs through several distinct biological processes, which not only vary between tumor type and anatomic location, but also occur simultaneously within the same cancer tissue. These processes are orchestrated by a range of secreted factors and signaling pathways and can involve participation of non-endothelial cells, such as progenitors or cancer stem cells. Anti-angiogenic therapies using either antibodies or tyrosine kinase inhibitors have been approved to treat several types of cancer. However, the benefit of treatment has so far been modest, some patients not responding at all and others acquiring resistance. It is becoming increasingly clear that blocking tumors from accessing the circulation is not an easy task to accomplish. Tumor vessel functionality and gene expression often differ vastly when comparing different cancer subtypes, and vessel phenotype can be markedly heterogeneous within a single tumor. Here, we summarize the current understanding of cellular and molecular mechanisms involved in tumor angiogenesis and discuss challenges and opportunities associated with vascular targeting.
Subfields: Cancer Research, Molecular Biology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/576bd9425889dff8a2a2f6356455582cdae39d2a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
Citations in the corpus
- Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “Common serious adverse events such as hypertension, proteinuria, lymphopenia, thrombocytopenia, leukopenia, neutropenia, and some physical abnormalities caused by different drugs have appeared in a number of different clinical treatments (Table 1), which may affect the tolerance of patients and even”